China Medical System Holdings (HKEX: 0867), headquartered in Hong Kong, has received clinical trial approval from China’s National Medical Products Administration (NMPA) to study its selective TYK2 inhibitor CMS-D001 in ulcerative colitis (UC) and Crohn’s disease (CD), adding two inflammatory bowel disease indications to a development programme that already spans psoriasis and atopic dermatitis.
CMS-D001 is an oral small molecule that selectively inhibits TYK2 (tyrosine kinase 2), a member of the JAK kinase family that sits upstream of inflammatory cytokine signalling pathways driven by IL-23, IL-12, and type I interferons. By targeting TYK2 specifically, the molecule is designed to suppress cytokine-mediated immune activation while minimising off-target activity on JAK1, JAK2, and JAK3 — the kinases implicated in the safety liabilities, including thrombosis and cardiovascular events, that carry black box warnings for pan-JAK inhibitors such as Pfizer’s tofacitinib (Xeljanz).
The mechanistic rationale for a selective TYK2 inhibitor in IBD is grounded in the central role that IL-23 and IL-12 play in intestinal inflammation. Both cytokines signal through receptor complexes that require TYK2 activation, making TYK2 a logical intervention point in the pathological cascade underlying UC and CD. China Medical System said CMS-D001 exhibits enhanced precision in targeting these pathogenic mechanisms, and that its selectivity profile offers a differentiated safety proposition relative to broader JAK inhibitors currently used in clinical practice.
The proof-of-concept for selective TYK2 inhibition in an immune-mediated disease already exists in a related indication: Bristol Myers Squibb’s deucravacitinib (Sotyktu) became the first FDA-approved TYK2 inhibitor when it received clearance for moderate-to-severe plaque psoriasis in 2022. Deucravacitinib operates through an allosteric mechanism targeting the regulatory domain of TYK2, and its approval validated the hypothesis that TYK2 selectivity can deliver clinical efficacy with a cleaner safety profile than pan-JAK inhibition. CMS-D001 will need to demonstrate comparable or superior outcomes in its own indications, including in the more competitive IBD landscape.
UC and CD are the two primary subtypes of inflammatory bowel disease, both characterised by chronic, relapsing inflammation of the gastrointestinal tract. UC predominantly affects the colonic mucosa, presenting with abdominal pain, diarrhoea, and mucopurulent bloody stools. CD can involve the entire digestive tract and is associated with intestinal fistula, obstruction, weight loss, and a high rate of disability. Both conditions impose a prolonged disease course that substantially diminishes quality of life.
In China, the patient population for these diseases is growing. According to a Frost & Sullivan report cited by the company, the number of UC patients in China rose from approximately 279,000 in 2015 to around 400,000 in 2019, and is projected to reach 918,000 by 2030. CD prevalence in China is estimated at 1.4 to 3.0 per 100,000 population, with an annual incidence of approximately 0.5 to 1.0 per 100,000, though underdiagnosis and misdiagnosis mean the true burden is likely higher.
Current treatment options for mild-to-moderate IBD rely primarily on aminosalicylates and glucocorticoids. For moderate-to-severe disease, biologics and small-molecule targeted therapies are used, with JAK inhibitors demonstrating the highest clinical remission rates among small molecules. However, the company noted that the highest clinical remission rates with existing JAK inhibitors remain in the range of 30% to 40%, leaving a substantial proportion of patients without adequate disease control. This gap underpins the rationale for investigating a selective TYK2 inhibitor IBD programme.
The NMPA clinical trial approval for UC and CD is the third such authorization for CMS-D001. The molecule first received NMPA approval for clinical trials in psoriasis in January 2024, followed by atopic dermatitis in July 2025. A Phase I study in healthy subjects has been completed, and Phase II trials in psoriasis and atopic dermatitis are currently ongoing, with the first subject enrolled in each.
CMS-D001 is developed by Dermavon Holdings Limited, a subsidiary of China Medical System, which has exclusively licensed the IBD rights to the parent group. Dermavon retains rights to the dermatology indications. China Medical System framed the IBD approval explicitly within a portfolio strategy centred on digestive disease management. The group already markets Salofalk (mesalazine) for UC and CD, and Bioflor (saccharomyces boulardii sachets) for diarrhea. The company also noted pipeline synergies within Dermavon’s dermatology portfolio, which includes ruxolitinib phosphate cream and the investigational long-acting anti-IL-4Rα monoclonal antibody MG-K10. Future development of CMS-D001 in systemic lupus erythematosus is planned, though no regulatory filings for that indication have been announced.
The TYK2 inhibitor class has not yet produced an approved therapy in IBD. Several programmes are in development globally, but none has reached registration-stage trials at the time of this approval. The NMPA CMS-D001 clinical trial approval therefore places China Medical System among the earlier movers in investigating this mechanism specifically for IBD, with the completed Phase I data providing a safety foundation for the next stage of development.
This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/
Your email address will not be published. Required fields are marked *
Comment *
Name *
Email *
Website
Privacy
Terms
About Us
Copyright © 2026. AllSci Corp. All rights reserved.
